Bone‐Targeting Selenium‐Doped Carbon Dot‐Based Nanoparticles for Ferroptosis Suppression and Osteogenesis Against Postmenopausal Osteoporosis
Advanced Healthcare Materials · 2026-04 · 15 (14)
DOI: 10.1002/adhm.202505203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 03.02.2026. Verfasst von Jingcheng Cao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Hebei Medical University Third Hospital, Shijiazhuang, P. R. China. Hauptthemen laut MEDLINE: Ferroptosis, Osteogenesis, Selenium, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Key Research and Development Project, Hebei Provincial Project of Central Government-Guided Local Science and Technology Development Fund, Hebei Provincial Graduate Student Innovation Capacity Development Funding Program.
Abstract (Originalsprache)
Ferroptosis plays a critical role in postmenopausal osteoporosis (PMOP) pathogenesis, but targeted therapies remain limited. In this study, we have developed bone‐targeting selenium‐doped carbon dots conjugated with alendronate (ASCDs) with the dual functionality of suppressing ferroptosis and promoting osteogenesis. In vitro, ASCDs mitigated erastin‐induced ferroptosis in osteoblasts and bone‐marrow mesenchymal stem cells by activating the system Xc − ‐GSH‐GPX4 antioxidant pathway, which reduced lipid peroxidation and restored mitochondrial function. Furthermore, ASCDs induced ALP activation and mineralized nodule formation under ferroptosis conditions, and enhanced expression of osteogenic markers, including RUNX2, OPN, and OSX. In vivo, ASCDs demonstrated superior efficacy compared to non‐targeted selenium‐doped carbon dots (SCDs), significantly reversing trabecular bone loss in ovariectomized mice, reducing osteoclast activity, and suppressing ferroptosis in bone tissue. Proteomics and biochemical analyses further validated that ASCDs exert therapeutic effects by rescuing GPX4 expression and redox homeostasis. Such dual‐functional carbon dots present a targeted strategy to treat PMOP by concurrently inhibiting ferroptosis and restoring bone formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Hebei Medical University Third Hospital, Shijiazhuang, P. R. China.
- Key Laboratory of Biomechanics of Hebei Province, NHC Key Laboratory of Intelligent Orthopaedic Equipment, Orthopedic Research Institution of Hebei Province, Shijiazhuang, P. R. China.
- Engineering Research Center of Orthopedic Minimally Invasive Intelligent Equipment, China Ministry of Education, Shijiazhuang, P. R. China.
- Key Laboratory of Precise Assessment, Diagnosis, and Treatment of Soft Tissue Injury of Hebei Province, Shijiazhuang, P. R. China.
ORCID-Profile: Jingcheng Cao, Wei Chen, Zhiyong Hou
Förderung
- National Key Research and Development Project
- Hebei Provincial Project of Central Government-Guided Local Science and Technology Development Fund
- Hebei Provincial Graduate Student Innovation Capacity Development Funding Program
- National-Level Scientific Research Innovation Team Cultivation Project of Xinjiang Medical University
Zitieren
APA
Cao, J., Dong, Q., Du, K., Zhang, M., Chen, W., & Hou, Z. (2026). Bone‐Targeting Selenium‐Doped Carbon Dot‐Based Nanoparticles for Ferroptosis Suppression and Osteogenesis Against Postmenopausal Osteoporosis. Advanced Healthcare Materials, 15(14). https://doi.org/10.1002/adhm.202505203
Vancouver
Cao J, Dong Q, Du K, Zhang M, Chen W, Hou Z. Bone‐Targeting Selenium‐Doped Carbon Dot‐Based Nanoparticles for Ferroptosis Suppression and Osteogenesis Against Postmenopausal Osteoporosis. Advanced Healthcare Materials. 2026;15(14). doi:10.1002/adhm.202505203
BibTeX
@article{Cao2026,
author = {Cao, Jingcheng and Dong, Qi and Du, Kezheng and Zhang, Mo and Chen, Wei and Hou, Zhiyong},
title = {Bone‐Targeting Selenium‐Doped Carbon Dot‐Based Nanoparticles for Ferroptosis Suppression and Osteogenesis Against Postmenopausal Osteoporosis},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {14},
doi = {10.1002/adhm.202505203}
}
EUVIMED